Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HSK0935 is a highly selective and orally available SGLT2 inhibitor (IC50: 1.3 nM). It has antihyperglycemic activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,420.00 | |
50 mg | 6-8 weeks | $ 1,850.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | HSK0935 is a highly selective and orally available SGLT2 inhibitor (IC50: 1.3 nM). It has antihyperglycemic activities. |
Targets&IC50 | SGLT2:1.3 nM |
In vitro | HSK0935 shows excellent hSGLT2 inhibition of 1.3 nM. HSK0935 displays a high hSGLT1/hSGLT2 selectivity of 843-fold[1]. |
In vivo | HSK0935 is well tolerated up to 300 mg/kg without any mortality or severe untoward effects in a 28-day repeat-dose toxicology study in beagle dogs. HSK0935 treatment (1, 3, and 10 mg/kg) displays robust urinary glucose excretion in Sprague?Dawley (SD) rats and affects more urinary glucose excretion in Rhesus monkeys[1]. |
Synonyms | HSK 0935, HSK-0935 |
Molecular Weight | 436.88 |
Formula | C22H25ClO7 |
CAS No. | 1638851-44-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HSK0935 1638851-44-1 GPCR/G Protein SGLT HSK 0935 HSK-0935 inhibitor inhibit